A detailed history of China Universal Asset Management Co., Ltd. transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 11,151 shares of CGEM stock, worth $122,103. This represents 0.02% of its overall portfolio holdings.

Number of Shares
11,151
Previous 6,771 64.69%
Holding current value
$122,103
Previous $118,000 57.63%
% of portfolio
0.02%
Previous 0.02%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$16.03 - $20.86 $70,211 - $91,366
4,380 Added 64.69%
11,151 $186,000
Q2 2024

Jul 19, 2024

SELL
$15.63 - $29.35 $34,776 - $65,303
-2,225 Reduced 24.73%
6,771 $118,000
Q1 2024

Apr 29, 2024

BUY
$10.17 - $19.02 $41,107 - $76,878
4,042 Added 81.59%
8,996 $153,000
Q4 2023

May 21, 2024

SELL
$7.89 - $10.23 $31,891 - $41,349
-4,042 Reduced 44.93%
4,954 $50,000
Q4 2023

Jan 23, 2024

BUY
$7.89 - $10.23 $30,447 - $39,477
3,859 Added 352.42%
4,954 $50,000
Q3 2023

May 21, 2024

BUY
$9.05 - $11.72 $5,239 - $6,785
579 Added 112.21%
1,095 $9,000
Q3 2023

Oct 30, 2023

BUY
$9.05 - $11.72 $5,239 - $6,785
579 Added 112.21%
1,095 $10,000
Q2 2023

May 21, 2024

SELL
$8.8 - $13.4 $149 - $227
-17 Reduced 3.19%
516 $5,000
Q2 2023

Jul 27, 2023

SELL
$8.8 - $13.4 $149 - $227
-17 Reduced 3.19%
516 $6,000
Q1 2023

May 21, 2024

BUY
$10.2 - $11.91 $693 - $809
68 Added 14.62%
533 $5,000
Q1 2023

Apr 27, 2023

BUY
$10.2 - $11.91 $693 - $809
68 Added 14.62%
533 $5,000
Q4 2022

May 21, 2024

SELL
$9.72 - $13.62 $82,921 - $116,192
-8,531 Reduced 94.83%
465 $4,000
Q4 2022

Jan 31, 2023

BUY
$9.72 - $13.62 $369 - $517
38 Added 8.9%
465 $5,000
Q3 2022

Oct 21, 2022

BUY
$11.82 - $15.42 $5,047 - $6,584
427 New
427 $5,000

Others Institutions Holding CGEM

About Cullinan Oncology, Inc.


  • Ticker CGEM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,612,200
  • Market Cap $499M
  • Description
  • Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...
More about CGEM
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.